Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm

Nucl Med Commun. 1998 Aug;19(8):743-51. doi: 10.1097/00006231-199808000-00004.


This study presents data on the dynamic distribution and dosimetry of 111In- and 99Tcm-labelled human non-specific immunoglobulin G (IgG), two recently developed radiopharmaceuticals for the detection of infection and inflammation. Five healthy volunteers were injected with 20-75 MBq 111In-IgG and seven patients were injected with 740 MBq 99Tcm-hydrazinonicotinamide derivative (HYNIC)-IgG. Blood samples, urine and feces were collected. Whole-body gamma camera imaging studies were performed. The activity in source organs was quantified using the conjugate view counting method and a partial background subtraction technique. Dosimetric calculations were performed using the MIRD technique. For 111In-IgG, the mean biological half-times in the blood were 0.90 and 46 h for the a- and b-phase, respectively. For 99Tcm-HYNIC-IgG, these half times were 0.46 and 45 h. For 111In-IgG, the mean cumulative urinary excretion in the first 48 h was 18% of the injected dose, while excretion in the feces was less than 2% of the injected dose. For 99Tcm-HYNIC-IgG, the whole-body retention was always 100% up to 24 h. The mean absorbed doses in the liver, spleen, kidneys, red marrow and testes from 111In-IgG were 0.8, 0.7, 1.2, 0.3 and 0.4 mGy MBq-1 respectively. The mean absorbed doses for 99Tcm-HYNIC-IgG to these organs were 16, 24, 15, 10 and 22 mu Gy MBq-1 respectively. The mean effective dose was 0.25 mSv MBq-1 and 8.4 mu Sv MBq-1 for 111In-IgG and 99Tcm-HYNIC-IgG respectively. In conclusion, the radiation absorbed doses for both 111In-IgG and 99Tcm-HYNIC-IgG are low and, therefore, these radiopharmaceuticals can be administered safely from a radiation risk perspective.

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Immunoglobulin G* / administration & dosage
  • Immunoglobulin G* / metabolism
  • Indium Radioisotopes* / administration & dosage
  • Indium Radioisotopes* / pharmacokinetics
  • Infections / diagnostic imaging
  • Inflammation / diagnostic imaging
  • Male
  • Middle Aged
  • Organotechnetium Compounds* / administration & dosage
  • Organotechnetium Compounds* / pharmacokinetics
  • Radiation Dosage
  • Radioimmunodetection / methods*
  • Radiopharmaceuticals* / administration & dosage
  • Radiopharmaceuticals* / pharmacokinetics
  • Tissue Distribution


  • Immunoglobulin G
  • Indium Radioisotopes
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • technetium Tc 99m hydrazinonicotinate-IgG